Is this Cancer-Fighting Biotech for Sale?
This episode of The Motley Fool's Market Checkup drills down on the days hottest headlines, highlighting the stories and stocks that should be on the radar of all investors. Market Checkup gives a full examination of the recent regulatory action around a new super-fish-oil drug, and looks at yet another biotech putting itself up for sale.
In this video, health-care analysts David Williamson and Max Macaluso discuss cancer-fighting biotech Clovis Oncology's rumored decision to hang a "for sale" sign on its front door. Watch and find out about Clovis's intriguing drug pipeline, how this fits within a broader trend of biotech M&A activity, and whether investors should jump aboard the stock's bandwagon.
David and Max conclude by discussing two topics they are watching closely; Clovis competitor Biomarin's R&D day, and the action in Congress over defunding the Affordable Care Act.
All about Obamacare
Still in the dark about how Obamacare might affect you and your portfolio? Don't worry -- you're not alone. To help prepare investors for the massive changes coming to the American health care system, The Motley Fool created a special free report that makes this complex topic easily understandable. Download, "Everything You Need to Know About Obamacare," and discover how the law may impact your taxes, health insurance, and investments. Click here for your free copy today.
Follow David on Twitter: @MotleyDavid.
The article Is this Cancer-Fighting Biotech for Sale? originally appeared on Fool.com.
David Williamson owns shares of Pfizer, Merck, and AbbVie, Follow David on Twitter: @MotleyDavid. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends BioMarin Pharmaceutical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.